Published in Ann Intern Med on June 17, 2008
The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med (2010) 2.71
Management of human immunodeficiency virus infection in advanced age. JAMA (2013) 1.51
HIV infection and older Americans: the public health perspective. Am J Public Health (2012) 1.31
Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med (2010) 1.01
The new invincibles: HIV screening among older adults in the U.S. PLoS One (2012) 0.99
HIV screening in the health care setting: status, barriers, and potential solutions. Mayo Clin Proc (2012) 0.98
A 10-year population based study of 'opt-out' HIV testing of tuberculosis patients in Alberta, Canada: national implications. PLoS One (2014) 0.91
A cost-effectiveness analysis of alternative HIV retesting strategies in sub-saharan Africa. J Acquir Immune Defic Syndr (2011) 0.85
Early diagnosis and treatment of HIV infection: magnitude of benefit on short-term mortality is greatest in older adults. Age Ageing (2013) 0.83
Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. Clin Infect Dis (2009) 0.82
Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. J Acquir Immune Defic Syndr (2013) 0.80
Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol (2011) 0.80
Epidemiological and mortality analysis of older adults with HIV in eastern China. Clin Interv Aging (2013) 0.78
A budget impact analysis of rapid human immunodeficiency virus screening in Veterans Administration emergency departments. J Emerg Med (2011) 0.78
Assessment and improvement of HIV screening rates in a Midwest primary care practice using an electronic clinical decision support system: a quality improvement study. BMC Med Inform Decis Mak (2016) 0.75
How Underestimates of Need Contribute to Biased Conclusions. Sex Transm Dis (2016) 0.75
Economic and health implications from earlier detection of HIV infection in the United Kingdom. HIV AIDS (Auckl) (2016) 0.75
Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis. Lancet HIV (2017) 0.75
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep (2006) 37.28
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA (1996) 14.23
A study of sexuality and health among older adults in the United States. N Engl J Med (2007) 9.66
Advancing HIV prevention: new strategies for a changing epidemic--United States, 2003. MMWR Morb Mortal Wkly Rep (2003) 9.37
A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med (1994) 8.52
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Markov models in medical decision making: a practical guide. Med Decis Making (1994) 8.14
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med (2005) 7.98
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med (1996) 7.06
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med (1995) 6.90
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health (2001) 6.29
The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med (1998) 6.26
The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89
Seroprevalence of HIV and risk behaviors among young homosexual and bisexual men. The San Francisco/Berkeley Young Men's Survey. JAMA (1994) 5.83
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
A randomized controlled trial of an HIV sexual risk-reduction intervention for young African-American women. JAMA (1995) 5.09
Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med (1999) 5.05
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet (1999) 4.68
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 4.54
The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making (1993) 4.46
Scope of the AIDS epidemic in the United States. Science (1995) 4.43
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis (2006) 3.72
Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol (1997) 3.66
Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med (2001) 3.64
The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group. Science (1998) 3.60
Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med (1997) 3.53
Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA (1996) 3.50
Natural history of HIV-1 cell-free viremia. JAMA (1995) 2.58
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
On-site, rapid HIV testing with same-day results and counseling. AIDS (1997) 2.44
Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med (2000) 2.42
Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med (2005) 2.38
Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA (1998) 2.37
Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group. JAMA (1998) 2.36
Emergency department-based HIV screening and counseling: experience with rapid and standard serologic testing. Ann Emerg Med (1999) 2.31
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS (2002) 2.21
Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis (2001) 2.19
Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet (1995) 2.17
A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making (2002) 2.12
Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med (2007) 2.07
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS (1997) 1.97
Rapid HIV testing at home: does it solve a problem or create one? Ann Intern Med (2006) 1.94
AIDS risk behaviors among late middle-aged and elderly Americans. The National AIDS Behavioral Surveys. Arch Intern Med (1994) 1.94
Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. CDC-Bronx-Lebanon HIV Serosurvey Team. Ann Intern Med (1996) 1.90
HIV infection in older patients in the HAART era. J Antimicrob Chemother (2005) 1.90
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med (2000) 1.88
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med (1998) 1.88
HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS (1999) 1.86
Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Ann Intern Med (1989) 1.84
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS (1998) 1.81
Routinely recommended HIV testing at an urban urgent-care clinic--Atlanta, Georgia, 2000. MMWR Morb Mortal Wkly Rep (2001) 1.78
Failure to return for HIV test results among persons at high risk for HIV infection: results from a multistate interview project. J Acquir Immune Defic Syndr (2004) 1.75
Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med (1994) 1.72
Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS (2004) 1.67
Fat distribution and metabolic changes in patients with HIV infection. AIDS (1999) 1.67
Characteristics of persons with heterosexually acquired HIV infection, United States 1999-2004. Am J Public Health (2006) 1.66
Heterosexual transmission of HIV in Haiti. Ann Intern Med (1996) 1.62
Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol (1997) 1.62
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA (1998) 1.59
Voluntary HIV testing as part of routine medical care--Massachusetts, 2002. MMWR Morb Mortal Wkly Rep (2004) 1.57
Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS (2004) 1.54
Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS (1998) 1.54
Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984-1989. J Acquir Immune Defic Syndr (1993) 1.53
Evaluation of a hospital admission HIV antibody voluntary screening program. Infect Control Hosp Epidemiol (1990) 1.50
Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making (2003) 1.49
Diagnosis and reporting of HIV and AIDS in states with integrated HIV and AIDS surveillance--United States, January 1994-June 1997. MMWR Morb Mortal Wkly Rep (1998) 1.48
Analysis of HIV-1 clinical trials: statistical magic? The AVANTI Steering Committee. Lancet (1999) 1.45
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. J Acquir Immune Defic Syndr (1999) 1.44
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS (1998) 1.43
Switching HIV-1 protease inhibitor therapy: which? When? And why? Arch Intern Med (1999) 1.41
Feasibility of an emergency department-based, risk-targeted voluntary HIV screening program. Ann Emerg Med (1996) 1.40
Predictors of optimal virological response to potent antiretroviral therapy. AIDS (1999) 1.40
Orogenital sex and the transmission of HIV among homosexual men. AIDS (1992) 1.39
The will to live among HIV-infected patients. Ann Intern Med (1999) 1.35
CD4+ T-lymphocyte measures in the treatment of individuals infected with human immunodeficiency virus type 1. A review for clinical practitioners. Arch Intern Med (1994) 1.29
Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.28
Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy. AIDS (2001) 1.27
Failure to return for HIV posttest counseling in an STD clinic population. AIDS Educ Prev (2003) 1.26
Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med (2006) 1.24
Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS (2001) 1.23
Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis (2006) 1.23
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses (1999) 1.22
Differences in symptom expression in older HIV-positive patients: The Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr (2003) 1.21
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis (1998) 1.20
Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med (2007) 9.88
Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA (2006) 9.36
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med (2005) 7.98
Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med (2005) 7.46
Effect of home testing of international normalized ratio on clinical events. N Engl J Med (2010) 5.36
Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. Ann Intern Med (2010) 5.14
Systematic review: surveillance systems for early detection of bioterrorism-related diseases. Ann Intern Med (2004) 4.58
Quality improvement strategies for hypertension management: a systematic review. Med Care (2006) 4.29
Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med (2008) 4.28
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16
Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med (2003) 3.88
Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine (Phila Pa 1976) (2009) 3.45
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med (2007) 3.17
Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2007) 3.14
Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med (2007) 3.10
Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? Clin Infect Dis (2008) 3.10
Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med (2007) 3.03
Systematic review: elective induction of labor versus expectant management of pregnancy. Ann Intern Med (2009) 3.01
Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med (2008) 2.96
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med (2004) 2.89
Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med (2006) 2.80
Payments for care at private for-profit and private not-for-profit hospitals: a systematic review and meta-analysis. CMAJ (2004) 2.76
Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from theAmerican College of Physicians. Ann Intern Med (2014) 2.75
The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med (2010) 2.71
Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 2.69
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2007) 2.69
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med (2014) 2.69
Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med (2011) 2.68
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 2.65
siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl (2007) 2.61
Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. Ann Intern Med (2006) 2.49
The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med (2012) 2.34
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Diagnostic imaging for low back pain: advice for high-value health care from the American College of Physicians. Ann Intern Med (2011) 2.29
Cost-effectiveness of elective induction of labor at 41 weeks in nulliparous women. Am J Obstet Gynecol (2010) 2.22
Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol (2009) 2.18
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int (2003) 2.18
Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Res (2011) 2.11
Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med (2013) 2.05
Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation (2010) 2.00
Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 1.98
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 1.92
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90
Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 1.83
Evaluation of primary care patients with chronic stable angina: guidelines from the American College of Physicians. Ann Intern Med (2004) 1.78
The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med (2010) 1.76
Cost-effectiveness of helicopter versus ground emergency medical services for trauma scene transport in the United States. Ann Emerg Med (2013) 1.74
Use of other opioids during methadone therapy: a population-based study. Addiction (2012) 1.72
Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med (2007) 1.72
Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA (2010) 1.71
Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med (2005) 1.69
Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med (2009) 1.68
Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerg Infect Dis (2016) 1.68
Transcatheter aortic valve replacement in nonsurgical candidates with severe, symptomatic aortic stenosis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes (2013) 1.68
Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. J Gen Intern Med (2008) 1.67
Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv (2008) 1.66
Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med (2008) 1.65
Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. Am J Med (2003) 1.63
Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med (2011) 1.62
Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med (2003) 1.61
Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator. Health Aff (Millwood) (2005) 1.60
HIV infection in the elderly. Clin Interv Aging (2008) 1.59
The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS One (2012) 1.58
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol (2004) 1.55
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med (2007) 1.54
Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer (2009) 1.50
Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One (2013) 1.49
Maternal and neonatal outcomes of elective induction of labor. Evid Rep Technol Assess (Full Rep) (2009) 1.49
Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS (2006) 1.48
Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2004) 1.45
Implementing effective hypertension quality improvement strategies: barriers and potential solutions. J Clin Hypertens (Greenwich) (2008) 1.44
Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med (2010) 1.41
Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure. Ann Intern Med (2015) 1.39
Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med (2003) 1.33
Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. Ann Intern Med (2009) 1.33
Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. Am J Kidney Dis (2007) 1.31
Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2009) 1.30
Management of obstructive sleep apnea in adults: A clinical practice guideline from the American College of Physicians. Ann Intern Med (2013) 1.27
A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol (2011) 1.26
Novel targets for antiretroviral therapy: clinical progress to date. Drugs (2009) 1.25
Exploring disability from the perspective of adults living with HIV/AIDS: development of a conceptual framework. Health Qual Life Outcomes (2008) 1.24
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making (2012) 1.24
Challenges in systematic reviews: synthesis of topics related to the delivery, organization, and financing of health care. Ann Intern Med (2005) 1.20
Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opin Drug Saf (2009) 1.19
Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr (2009) 1.19
Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS (2011) 1.18
The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res (2006) 1.18